GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report)’s stock price traded down 4.1% during mid-day trading on Thursday . The stock traded as low as $25.10 and last traded at $25.11. 121,288 shares were traded during trading, a decline of 67% from the average session volume of 371,080 shares. The stock had previously closed at $26.19.
Analysts Set New Price Targets
WGS has been the topic of several recent research reports. TD Cowen boosted their price objective on shares of GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Jefferies Financial Group began coverage on shares of GeneDx in a research report on Monday, June 3rd. They issued a “hold” rating and a $21.00 price target on the stock. The Goldman Sachs Group lifted their price objective on GeneDx to $11.00 and gave the stock a “neutral” rating in a research report on Monday, April 15th. Finally, BTIG Research increased their target price on GeneDx from $19.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday.
GeneDx Trading Up 1.7 %
The business’s fifty day moving average price is $21.20 and its 200 day moving average price is $11.28. The company has a quick ratio of 2.99, a current ratio of 3.22 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $695.84 million, a PE ratio of -5.02 and a beta of 2.21.
GeneDx (NASDAQ:WGS – Get Free Report) last released its earnings results on Monday, April 29th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.35. The firm had revenue of $62.42 million during the quarter, compared to analysts’ expectations of $49.80 million. GeneDx had a negative net margin of 60.86% and a negative return on equity of 36.23%. As a group, analysts expect that GeneDx Holdings Corp. will post -0.92 EPS for the current fiscal year.
Insider Activity at GeneDx
In other GeneDx news, CFO Kevin Feeley sold 2,646 shares of GeneDx stock in a transaction on Monday, June 17th. The shares were sold at an average price of $28.31, for a total value of $74,908.26. Following the transaction, the chief financial officer now owns 37,409 shares in the company, valued at approximately $1,059,048.79. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Katherine Stueland sold 6,325 shares of GeneDx stock in a transaction on Monday, April 29th. The shares were sold at an average price of $11.04, for a total transaction of $69,828.00. Following the transaction, the chief executive officer now owns 75,869 shares in the company, valued at approximately $837,593.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 2,646 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $28.31, for a total value of $74,908.26. Following the completion of the sale, the chief financial officer now owns 37,409 shares of the company’s stock, valued at $1,059,048.79. The disclosure for this sale can be found here. Over the last ninety days, insiders acquired 175,804 shares of company stock worth $3,771,670 and sold 21,305 shares worth $462,821. Insiders own 28.10% of the company’s stock.
Institutional Investors Weigh In On GeneDx
Several institutional investors and hedge funds have recently modified their holdings of the stock. Thompson Davis & CO. Inc. lifted its position in GeneDx by 99.4% during the 4th quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock worth $55,000 after acquiring an additional 9,944 shares in the last quarter. PFG Investments LLC purchased a new position in shares of GeneDx in the first quarter valued at $95,000. Decheng Capital LLC acquired a new stake in GeneDx during the 4th quarter valued at $285,000. HighTower Advisors LLC increased its stake in GeneDx by 14.1% during the 3rd quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock worth $865,000 after buying an additional 29,361 shares during the period. Finally, Gagnon Advisors LLC lifted its holdings in GeneDx by 41.6% in the 1st quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock worth $1,930,000 after buying an additional 62,059 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.